Aclitol Dry Powder Inhalation Capsule (DPI) 400 mcg + 12 mcg

Aclitol is a combination inhaler containing Aclidinium Bromide + Formoterol Fumarate, manufactured by Square Pharmaceuticals PLC. Priced at ৳25.00 per unit (2×10 capsules: ৳500), it treats chronic obstructive pulmonary disease (COPD) by reducing airway obstruction through dual bronchodilation.

This dry powder inhalation capsule (DPI) combines a long-acting muscarinic antagonist (LAMA) and a long-acting beta2-agonist (LABA). The 400 mcg/12 mcg strength ensures 24-hour symptom control when used twice daily. Patients must avoid exceeding two inhalations daily to prevent adverse effects.

Pharmacologically, Aclidinium blocks M3 receptors for sustained airway relaxation, while Formoterol activates beta2 receptors for rapid bronchodilation. Their synergy enhances lung function in COPD. Clinical studies show improved exercise tolerance and reduced exacerbations.

Key precautions include avoiding concurrent anticholinergics and monitoring for hypokalemia with diuretics. Common side effects (3%+) include headaches and upper respiratory infections. Store below 25°C, protected from moisture and light.

Explore Aclidinium + Formoterol alternatives for cost-effective options. Always consult healthcare providers before switching medications or adjusting doses.

One inhalation capsule (400/12μg) twice daily via DPI device. No dosage adjustment needed for renal/hepatic impairment. Continue as long as clinically beneficial.

Most common adverse reactions (incidence 3% and more common than with placebo) include: upper respiratory tract infection and headache.

Pregnancy Category C. Use only if benefit outweighs risk. Unknown if excreted in breast milk – consult physician.

Not for acute COPD attacks. Use only with approved Square Pharmaceuticals inhaler device. Monitor glucose in diabetic patients.

Safe in elderly. No pediatric data. Hepatic/renal impairment requires no dose adjustment. Limited safety data in pregnancy.